Taraxasterol

The marquee, and the most replicated. Taraxasterol reduced paw swelling and cytokines in rat adjuvant-induced arthritis ^{1Reference 1Wang S et al. · 2016AnimalAnti-inflammatory and anti-arthritic effects of taraxasterol on adjuvant-induced arthritis in ratsView study →}, limited inflammation and apoptosis in ulcerative colitis ^{2Reference 2Che X et al. · 2019In vitroAnti-inflammatory and anti-apoptotic activity of taraxasterol in ulcerative colitis in vitro and in vivoView study →}, protected against LPS acute lung injury ^{3Reference 3Zhang X et al. · 2014AnimalProtective effect of taraxasterol on acute lung injury induced by lipopolysaccharide in miceView study →}, and suppressed macrophage hyperactivation in sepsis-induced ARDS ^{4Reference 4Bu C et al. · 2022AnimalTaraxasterol inhibits hyperactivation of macrophages to alleviate the sepsis-induced inflammatory response of ARDS ratsView study →} — converging on NF-κB p65, MAPK, COX-2 and iNOS.

Gap: every model is rodent or cell-based, with no human inflammatory-disease data and no head-to-head against a standard anti-inflammatory at an achievable oral exposure ^{1,3Reference 1Wang S et al. · 2016AnimalAnti-inflammatory and anti-arthritic effects of taraxasterol on adjuvant-induced arthritis in ratsView study →Reference 3Zhang X et al. · 2014AnimalProtective effect of taraxasterol on acute lung injury induced by lipopolysaccharide in miceView study →}.

Taraxasterol dampened Th2 cytokines and eosinophilia in an ovalbumin allergic-asthma model ^{6Reference 6Liu J et al. · 2013AnimalEffects of taraxasterol on ovalbumin-induced allergic asthma in miceView study →} and suppressed macrophage hyperactivation in sepsis/ARDS ^{4Reference 4Bu C et al. · 2022AnimalTaraxasterol inhibits hyperactivation of macrophages to alleviate the sepsis-induced inflammatory response of ARDS ratsView study →} — reading as broad innate plus Th2-axis damping.

Gap: no adaptive-immunity dose-response or immune-competence data, entirely preclinical, with mechanism inferred from downstream cytokines ^{6,4Reference 6Liu J et al. · 2013AnimalEffects of taraxasterol on ovalbumin-induced allergic asthma in miceView study →Reference 4Bu C et al. · 2022AnimalTaraxasterol inhibits hyperactivation of macrophages to alleviate the sepsis-induced inflammatory response of ARDS ratsView study →}.

Taraxasterol protected against acetaminophen-induced liver injury via Nrf2/HO-1 with JNK and Bax/Bcl-2 modulation ^{10,11Reference 10Ge W et al. · 2023Protection of taraxasterol against acetaminophen-induced liver injury elucidated through network pharmacology and in-vitro and in-vivo experimentsView study →Reference 11Lin W et al. · 2024AnimalTaraxasterol protects against acetaminophen-induced hepatotoxicity by reducing liver inflammation and ameliorating oxidative stress in miceView study →} and attenuated D-galactosamine/LPS fulminant hepatitis through JAK/STAT and TNF signaling ^{12Reference 12Wang G et al. · 2025Taraxasterol attenuated D-galactosamine/LPS-induced fulminant hepatitis by modulating JAK/STAT and TNF signallingView study →}.

Gap: all acute chemical-injury models, with no chronic-liver-disease or human data, and the effect is largely secondary to the general anti-inflammatory/antioxidant mechanism ^{10,12Reference 10Ge W et al. · 2023Protection of taraxasterol against acetaminophen-induced liver injury elucidated through network pharmacology and in-vitro and in-vivo experimentsView study →Reference 12Wang G et al. · 2025Taraxasterol attenuated D-galactosamine/LPS-induced fulminant hepatitis by modulating JAK/STAT and TNF signallingView study →}.

Taraxasterol stabilized p53 via MDM2 degradation in pancreatic cancer ^{7Reference 7Han A et al. · 2025Taraxasterol regulates p53 transcriptional activity to inhibit pancreatic cancer by inducing MDM2 ubiquitination degradationView study →}, enhanced bladder-cancer radiosensitivity through COX-2/PGE2/JAK2/STAT3 inhibition ^{8Reference 8Wang Q et al. · 2024Taraxasterol enhanced bladder-cancer cell radiosensitivity via inhibiting the COX-2/PGE2/JAK2/STAT3/MMP pathwayView study →}, and showed a dual anti-aging/anti-cancer effect in lung cells ^{9Reference 9Xie J et al. · 2024Taraxasterol exhibits dual biological effects on anti-aging and anti-cancer in lung cellsView study →}.

Gap: heterogeneous, mostly single-lab cell-line/xenograft studies with non-overlapping mechanisms, no consistent signaling story and no clinical signal — the weakest ranked set despite the volume ^{7,8Reference 7Han A et al. · 2025Taraxasterol regulates p53 transcriptional activity to inhibit pancreatic cancer by inducing MDM2 ubiquitination degradationView study →Reference 8Wang Q et al. · 2024Taraxasterol enhanced bladder-cancer cell radiosensitivity via inhibiting the COX-2/PGE2/JAK2/STAT3/MMP pathwayView study →}.

Taraxasterol attenuated a 2,4-dinitrochlorobenzene atopic-dermatitis model via MAPK and NF-κB inactivation ^{5Reference 5Zhang Y et al. · 2025AnimalTaraxasterol attenuates inflammatory responses in a 2,4-dinitrochlorobenzene-induced atopic-dermatitis mouse model via inactivation of MAPK and NF-κBView study →} and reduced ovalbumin-induced allergic asthma ^{6Reference 6Liu J et al. · 2013AnimalEffects of taraxasterol on ovalbumin-induced allergic asthma in miceView study →}.

Gap: two models only, and the “anti-allergic” label is a re-framing of the same anti-inflammatory/Th2 mechanism rather than an independent evidence stream ^{5,6Reference 5Zhang Y et al. · 2025AnimalTaraxasterol attenuates inflammatory responses in a 2,4-dinitrochlorobenzene-induced atopic-dermatitis mouse model via inactivation of MAPK and NF-κBView study →Reference 6Liu J et al. · 2013AnimalEffects of taraxasterol on ovalbumin-induced allergic asthma in miceView study →}.